Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial

Citations Over TimeTop 10% of 2013 papers

Abstract

Although concurrent chemoradiotherapy was the standard care for locally advanced esophageal cancer, radiotherapy was the choice for those who were refused or could not tolerate chemoradiotherapy. Our study shows that nimotuzumab combined with radiotherapy was well tolerated in patients with esophageal cancer. EGFR overexpression was more common than previously reported. OS was higher after combined therapy than after historical control radiotherapy alone. Further studies are required to confirm the therapeutic efficacy of nimotuzumab in esophageal cancer.

Related Papers

• → Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.(2012)68 cited
• → Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma(2021)14 cited
• → Intense Esophageal FDG Activity Caused by Candida Infection Obscured the Concurrent Primary Esophageal Cancer on PET Imaging(2005)37 cited
• → Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC)(2006)8 cited
• EPIDEMIOLOGICAL FEATURES OF ESOPHAGEAL MUCOSAL LESION ON DIFFERENT SEX IN HIGH RISK POPULATION OF ESOPHAGEAL CANCER(1995)